At present,the world has entered the normalization stage of coronavirus disease 2019(COVID-19)management.COVID-19 continues to affect patients with allogeneic hematopoietic stem cell transplantation(allo-HSCT)for a long period.The author discussed the possible effect of COVID-19 on HSCT strategy and prognosis during this period based on literature reports.Transplantation should be deferred until clinical resolution and negative severe acute respiratory syndrome coronavirus 2(S ARS-CoV-2)in patients infected with SARS-CoV-2 before transplantation.Donors infected with SARS-CoV-2 during the stem cell collection may not affect apheresis.Allo-HSCT recipients demonstrated a high rate of severe COVID-19 if COVID-19 occurred at the early stage of transplantation.Severe COVID-19 remains a risk factor for nonrelapse mortality and survival after transplantation.The association between COVID-19 and post-transplantation complications,such as other infections,endothelial injury-related complications,and relapse,needs to be further investigated in large samples.
NETL
NSTL
万方数据
